20190184 20190184: EVOLVE-MI: A Pragmatic Randomized Multicenter Trial of EVOLocumab Administered Very Early to Reduce the Risk of Cardiovascular Events in Patients Hospitalized With Acute Myocardial Infarction

NCT05284747

20190184: EVOLVE-MI: A Pragmatic Randomized Multicenter Trial of EVOLocumab Administered Very Early to Reduce the Risk of Cardiovascular Events in Patients Hospitalized With Acute Myocardial Infarction

Principal Investigator

Sponsor

Amgen Inc.

This study is being done to learn whether regular healthcare, combined with early treatment with a cholesterol lowering drug called evolocumab (Repatha) reduces heart attack, stroke, procedures to improve blood flow and death, compared to regular healthcare alone.

This study is currently enrolling.